Highlights Previous influenza vaccination was associated with a reduced need for hospitalization after COVID-19 diagnosis. In 60 days of outpatient setting, four deaths occurred (three in the hospitalized and one in the non-hospitalized group). The persistence of more than two symptoms in 60 days was observed in 31.9% of patients. ABSTRACT Objective: To evaluate deaths, hospitalizations, and persistence of symptoms in patients with COVID-19 after infection in an outpatient setting during the first COVID-19 wave in Brazil. Methods: This prospective
The present systematic review and meta-analysis aimed to investigate the use of recombinant proteins to diagnose STIs and evaluate the performance of the tests identified. The databases, SciELO, PubMed, CAPES Journal Portal, and LILACS, were searched according to the PRISMA protocol. A study was considered eligible if it met previously defined criteria. The risk of study bias was assessed according to the QUADAS-2 protocol. The meta-analysis was performed based on the random-effects model, and heterogeneity was quantified using the I² statistic. A total of 1,355 studies were selected, 30 of which were relevant to the following: human immunodeficiency virus (12/30), Treponema pallidum (10/30), Chlamydia trachomatis (3/30), herpes simplex virus (HSV, 2/30), Trichomonas vaginalis (2/30), and HSV/cytomegalovirus (1/30). The main serological tests were ELISA and immunochromatography. The risk of bias was low for most included studies. According to each microorganism, the meta-analysis revealed satisfactory sensitivity and specificity for the analyzed tests. The findings reinforce the relevance of diagnostic tests based on recombinant proteins as viable alternatives for production and inclusion in clinical practice. PROSPERO registration number: CRD42020206331.